The Cost of a Cure 💊

Table of Contents

The Cost of a Cure

The price of human life; 3,120 USD. That’s what world governments will pay Gilead Sciences for one single patient’s remdesevir treatment.

Martin Shkreli vibes, anyone? Tough on the uninsured, the drug costs ten bucks to manufacture, it isn’t a cure; capitalism at its finest you might say. But Gilead’s been giving all its remdesivir away for free until now, and main street investors are still waiting to profit from the drug. The stock is up on expectation alone.

It will go up more if a vaccine is slow coming. It will go down if remdesivir’s been overproduced; only 2% of the world’s ten million infected have had a go on remdesivir, but Gilead is producing enough vials for 20% of the world’s infected. The drug isn’t free anymore for poorer countries, remember, so this stock has to be a bet on a second wave.

The other moving part here is competition and rival treatment candidates. There are hundreds; dexamethasone (a cheap steroid) has recently been found to stop coronavirus deaths, and on that, remdesivir’s pro-forma price crashed. It had been closer to $4,500. 

This doesn’t bode well for Gilead. It might not have any Covid-era competitive advantages. As Warren Buffett would say, “it might have a shallow moat,” or perhaps that’s not important when demand is this high!

Share:
More Posts
Higher Rate Households 📈

The recent Fed decision to pause rates has left the federal funds rate at its highest level since 2000.

Get your daily Invstr Crunch

Get the market news and updates you need, delivered to your inbox or available on our daily podcast.

Risk Disclosure:

Invstr is not a bank and banking services are provided by Vast Bank, N.A.

Brokerage and Banking services are currently only available to U.S. residents.

Invstr app and web services are provided by Invstr Ltd. Advisory services are provided by Invstr Financial LLC, an investment adviser registered with the Securities Exchange Commission (SEC) details of which can be obtained here. Securities brokerage and custody services are provided by Apex Clearing, a broker dealer registered with the SEC and a member of FINRA and SIPC. There is no bank guarantee on securities and securities may lose value.

Investing involves risk and can lead to losses. Past performance does not guarantee future results.

Invstr app and web services are provided by Invstr Ltd. Invstr+ advisory services are provided by Invstr Financial LLC, an investment adviser registered with the Securities Exchange Commission (SEC). Securities brokerage and custody services are provided by Apex Clearing, a broker dealer registered with the SEC and a member of FINRA and SIPC. There is no bank guarantee on securities and securities may lose value. Vast Bank N.A. a nationally chartered bank and member of the FDIC, provides the banking products, including the products and services related to digital asset accounts. As with any asset, the value of Digital assets can go up or down and there can be a substantial risk that you lose money buying or holding digital assets. You should carefully consider whether trading or holding Digital assets is suitable for you in light of your financial condition. Your digital account does not support wallet to wallet transferring of your digital assets (i.e. cryptocurrencies) outside the platform. Any Digital Assets in your digital asset account are not insured by any government entities, including but not limited to FDIC or SIPC. The Invstr Visa® Debit Card is issued by Vast Bank, N.A. pursuant to a license from Visa U.S.A Inc and may be used everywhere Visa debit cards are accepted. Invstr Ltd, Invstr Financial LLC and Invstr Securities Ltd are subsidiaries of Marketspringpad Holdings (collectively “Invstr”) and Invstr is solely responsible for the application services and website content.

Watchlists provided when users first access the service are not a recommendation to invest. Instead they are provided to help users better navigate the service. Users are free to edit and create their own watchlists. From time to time, Invstr will suggest instruments solely based on an individual’s interest and the interest levels of the Invstr community. The statistical and portfolio builder models generated by Invstr do not reflect actual investment results and are not guarantees of future results. Comments provided by Invstr leaders, influencers or members of the Invstr Community are not recommendations and should not be construed as such. Invstr does not endorse the content or the positions posted by them. Their investment approach, and that of the models provided by Invstr, may be different from yours and may not be appropriate for you.